Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision
Open Access
- 28 May 2020
- journal article
- review article
- Published by Walter de Gruyter GmbH in Radiology and Oncology
- Vol. 54 (3) , 272-277
Abstract
Background: Colorectal cancer (CRC) is one of the most common types of cancer in the world. Metastatic disease is still incurable in most of these patients, but the survival rate has improved by treatment with novel systemic chemotherapy and targeted therapy in combination with surgery. New knowledge of its complex heterogeneity in terms of genetics, epigenetics, transcriptomics and microenvironment, including prognostic and clinical characteristics, led to its classification into various molecular subtypes of metastatic CRC, called consensus molecular subtypes (CMS). The CMS classification thus enables the medical oncologists to adjust the treatment from case to case. They can determine which type of systemic chemotherapy or targeted therapy is best suited to a specific patient, what dosages are needed and in what order. Conclusions: CMS in metastatic CRC are the new tool to include the knowledge of molecular factors, tumour stroma and signalling pathways for personalized, patient-orientated systemic treatment in precision medicine.Keywords
This publication has 19 references indexed in Scilit:
- Treatment sequencing in metastatic colorectal cancerEuropean Journal of Cancer, 2019
- Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trialsAnnals of Oncology, 2019
- Colorectal Cancer Biomarkers in the Era of Personalized MedicineJournal of Personalized Medicine, 2019
- Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal CancerAmerican Society of Clinical Oncology Educational Book, 2018
- Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular SubtypesClinical Cancer Research, 2018
- Colorectal Cancers: An Update on Their Molecular PathologyCancers, 2018
- Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancerAnnals of Oncology, 2017
- Consensus molecular subtypes and the evolution of precision medicine in colorectal cancerNature Reviews Cancer, 2017
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology, 2016
- The consensus molecular subtypes of colorectal cancerNature Medicine, 2015